**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 46398**

**Manuscript Type: META-ANALYSIS**

**Genetic testing *vs* microforceps biopsy in pancreatic cysts: systematic review and meta-analysis**

Faias S *et al*. Genetics *vs* biopsies in pancreatic cysts

Sandra Faias, Luisa Pereira, Ângelo Luís, Paula Chaves, Marília Cravo

**Sandra Faias**, Department of Gastroenterology, Instituto Português de Oncologia de Lisboa de Francisco Gentil, EPE, Lisboa 1099-023, Portugal

**Sandra Faias**, **Paula Chaves**, Faculdade de Ciências da Saúde, Universidade da Beira Interior, Covilhã 6200-506, Portugal

**Sandra Faias**, **Luisa Pereira**, **Ângelo Luís**, GRUBI-Grupo de Revisões Sistemáticas, Universidade da Beira Interior, Covilhã 6200-506, Portugal

**Luisa Pereira**, Centro de Matemática e Aplicações (CMA-UBI), Universidade da Beira Interior, Covilhã 6200-506, Portugal

**Ângelo Luís**, Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Covilhã 6200-506, Portugal

**Paula Chaves**, Department of Pathology, Instituto Português de Oncologia de Lisboa de Francisco Gentil, EPE, Lisboa 1099-023, Portugal

**Marília Cravo**, Department of Gastroenterology, Hospital Beatriz Ângelo, Loures 2674-514, Portugal

**Marília Cravo**, Faculdade de Medicina, Universidade de Lisboa, Lisboa 1099-023, Portugal

**ORCID number:** Sandra Faias (0000-0002-3358-7288); Ângelo Luís (0000-0003-0712-6522); Luisa Pereira (0000-0002-9068-4607); Paula Chaves (0000-0002-0732-2059); Marília Cravo (0000-0001-8309-4599).

**Author contributions:**All authors have contributed to the study concept and design; Faias S, Pereira L and Luís Â acquired and interpreted the data and drafted the manuscript, under the supervision of all senior authors; Chaves P and Cravo M critically revised the manuscript; and all authors approved the final version of the manuscript.

**Conflict-of-interest statement:** The authors have no conflict of interest to disclose.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Sandra Faias, MD, Attending Doctor, Research Fellow,** Department of Gastroenterology, Instituto Português de Oncologia de Lisboa de Francisco Gentil, EPE, Lisboa 1099-023, Portugal. sfaias@ipolisboa.min-saude.pt

**Telephone:** +351-914310209

**Fax:** +351-217229855

**Received:** February 18, 2019

**Peer-review started:** February 18, 2019

**First decision:** April 8, 2019

**Revised:** April 17, 2019

**Accepted:** May 18, 2019

**Article in press:**

**Published online:**

**Abstract**

***Background***

Carcinoembryonic antigen (CEA) and cytology in pancreatic cystic fluid are suboptimal for evaluation of pancreatic cystic neoplasms. Genetic testing and microforceps biopsy are promising tools for pre-operative diagnostic improvement but comparative performance of both methods is unknown.

***Aim***

To compare the accuracy of genetic testing and microforceps biopsy in pancreatic cysts referred for surgery.

***Methods***

We performed a literature search in Medline, Scopus, and Web of Science for studies evaluating genetic testing of cystic fluid and microforceps biopsy of pancreatic cysts, with endoscopic ultrasound with fine-needle aspiration (EUS-FNA) prior to surgery and surgical pathology as reference standard for diagnosis. We evaluated the diagnostic accuracy for: 1- benign cysts; 2- mucinous low-risk cysts; 3- high-risk cysts, and the diagnostic yield and rate of correctly identified cysts with microforceps biopsy and molecular analysis. We also assessed publication bias, heterogeneity, and study quality.

***Results***

Eight studies, including 1206 patients, of which 203 (17%) referred for surgery who met the inclusion criteria were analyzed in the systematic review, and seven studies were included in the meta-analysis. Genetic testing and microforceps biopsies were identical for diagnosis of benign cysts. Molecular analysis was superior for diagnosis of both low and high-risk mucinous cysts, with sensitivities of 0.89 (95%CI: 0.79-0.95) and 0.57 (95%CI: 0.42-0.71), specificities of 0.88 (95%CI: 0.75-0.95) and 0.88 (95%CI: 0.80-0.93) and AUC of 0.9555 and 0.92, respectively. The diagnostic yield was higher in microforceps biopsies than in genetic analysis (0.73 *vs* 0.54, respectively) but the rates of correctly identified cysts were identical (0.73 with 95%CI: 0.62-0.82 *vs* 0.71 with 95%CI: 0.49-0.86, respectively).

***Conclusion***

Genetic testing and microforceps biopsies are useful second tests, with identical results in benign pancreatic cysts. Genetic analysis performs better for low- and high-risk cysts but has lower diagnostic yield.

**Key words:** Pancreatic cysts; Endoscopic ultrasound; Endoscopic ultrasound with fine-needle aspiration; Genetic testing; Microforceps biopsy; Molecular analysis; KRAS; Carcinoembryonic antigen; Cytology

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** With the increasing diagnosis of asymptomatic pre-malignant pancreatic cysts, there is a growing need for accurate and affordable diagnostic tests. The goal is to detect and resect early malignancy, while avoiding unnecessary follow-up in benign cysts and surgery in low-risk cysts. Genetic testing is promising, but with current diagnostic limitations, significant costs, logistic difficulties in preserving material for future analysis, and technical complexity, its generalized use seems difficult. If microforceps biopsy proves in larger studies to be safe and to allow correct diagnosis, it may be immediately implemented, because the endoscopic procedure is standard, and histology is widespread in clinics.

Faias S, Pereira L, Luís Â, Chaves P, Cravo M. Genetic testing *vs* microforceps biopsy in pancreatic cysts: systematic review and meta-analysis. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Pancreatic cystic neoplasms (PCNs) are on the rise in clinics due to an ageing population and the increase in routine use of high-quality abdominal imaging[1]. PCNs are generally classified into two main groups: mucinous cystic neoplasms (MCNs) and non-mucinous cystic neoplasms (NMCN). MCNs include intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystadenomas, which are precursor lesions of pancreatic carcinoma, and may be low-risk (pre-malignant with low or intermediate-grade atypia) or high-risk: pre-malignant with high-grade atypia (HGA) or malignant, including adenocarcinomas secondarily cystic. NMCNs include serous cystadenomas and inflammatory cysts (pseudocysts), mostly benign cysts, but may include some rare lesions, considered high-risk as cystic neuroendocrine tumors (cNETs), and acinar cell cystadenomas (ACCs). The heterogeneity in malignant potential, increased frequency, and significant morbidity and mortality of surgical treatment, makes pre-operative diagnosis of PCNs essential for management. The treatment options for PCNs encompass surgery or conservative surveillance for MCNs, according to malignancy risk, or no further evaluation for most NMCNs.

The differentiation between MCNs and NMCNs is critical, because a misdiagnosis of a MCN can lead to a missed opportunity to treat pancreatic cancer in an early stage and a misdiagnosis of NMCN can result in unnecessary surgery or surveillance with associated morbidity, costs, and negative impact on quality of life.

Currently, morphologic characterization of PCNs and pancreatic cystic fluid (PCF) analysis for carcinoembryonic Antigen (CEA) and cytology are central in diagnosis. A CEA level ≥ 192 ng/mL is the most accurate diagnostic test for MCNs and cytology is highly specific for malignancy[2], but with suboptimal results in large studies with surgical pathology as the gold standard[3]. In fact, a significant part of these lesions remains indeterminate and incorrect pre-operative diagnosis occurs in one third of patients[4,5], making new reliable diagnostic tools urgently needed.

In the last decade numerous studies have shown that genetic analysis of aspirates obtained by EUS-FNA provided a better characterization of PCNs than CEA and cytology[6-14]. Next-generation sequencing (NGS) is a very sensitive technique for detection of genetic mutations that allows the rapid detection of mutations in pre-defined panels of cancer genes, even in samples with limited DNA content, such as PCF. NGS requires storage, infrastructure, data processing, and expert personnel. Moreover, to be cost-effective, large numbers of samples need to be processed, making it applicable only in large centralized laboratories. These reasons make the implementation of NGS in clinical practice still a matter of debate.

The clinical need of better diagnostic tests in PCNs has recently led to the development of a through-the-needle miniature biopsy device for use during EUS-FNA[15,16]. The Moray micro forceps biopsy (MFB) device (US Endoscopy, Mentor, Ohio) is disposable and can pass through a standard 19-gauge EUS-FNA needle that is already used routinely. It allows tissue sampling from the cyst wall, septa or mural nodules and the obtention of a histological evaluation of the epithelial architecture and subepithelial stroma[17]. Adding to the high technical success and excellent safety profile[18,19], the new device has shown to improve the diagnostic accuracy of specific cyst subtypes[20,21]. Another major advantage of MFB is the simultaneous tissue sampling and PCF acquisition, with just an additional histologic analysis that follows standard definitions and is already routine in clinics.

The aim of this systematic review and meta-analysis is to evaluate the diagnostic performance of molecular analysis (MA) and MFB and find the most robust additional diagnostic technique in PCNs, in the pre-operative setting.

**Materials and methods**

This systematic review and meta-analysis is conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies, the PRISMA-DTA Statement[22], and the protocol is registered at PROSPERO (CRD42018111910).

***Literature search and study selection***

A comprehensive search of databases, including Medline, Scopus, and Web of Science, for the past 8 years (January 1st, 2010 to July 31st, 2018) and restricted to human studies was performed. No language restrictions were applied. The following search terms were used in two independent searches: “pancreas”, “cyst”, “molecular”, “analysis”; and “micro”, “forceps”, “microforceps”, “biopsy”. A search of related articles was performed, adding additional studies. Duplicate articles, reviews, trials including other kinds of neoplasms, and trials with molecular markers not compliant with the defined inclusion criteria were removed. The references of all selected studies were hand-searched for additional articles.

**Inclusion criteria:** Published studies were included in the meta-analysis if they analyzed: (1) patients with symptomatic or incidental pancreatic cysts with a definitive surgical pathology diagnosis; (2) genetic mutations performed with high sensitive techniques, such as NGS in PCF obtained by EUS-FNA prior to surgery; (3) at least four genetic mutations, including *KRAS, GNAS, VHL*, and at least another genetic mutation representative of aggressive neoplasms (*PIK3CA, TP53, SMAD4, PTEN, CDKN2A*); (4) PCNs evaluated by EUS-FNA with MFB for diagnosis; and (5) surgical pathology specimens with available data.

**Exclusion criteria:** (1) Studies of MA with fewer than the four genetic mutations previously defined; (2) studies involving solid pancreatic lesions; (3) studies using PCF not obtained by EUS-FNA; (4) reviews, case reports, case series with fewer than five patients, letters to editor, exploratory studies, and papers published only in abstract form; (5) studies with cytology and clinical surveillance as standard of diagnosis. Two authors (SF and AL) independently judged study eligibility and disagreements were resolved by consensus.

**Histological criteria:** We classified the PCNs of the included studies into three main groups: (1) high-risk cysts (adenocarcinoma or high grade dysplasia in IPMNs and MCNs, secondarily cystic adenocarcinomas, cNETs, and ACCs; (2) low-risk mucinous cysts (IPMNs and MCNs with intermediate or low-grade dysplasia); and (3) benign cysts (SCAs, pseudocysts, and other rare cysts (RCs) included in some articles, as retention cysts, lymphoepithelial cysts, epidermoid cysts, squamoid cysts).

**Tests under investigation:** The index tests were: (1) MA of PCF; and (2) MFB of PCNs, including cyst wall, septs, and nodules. A diagnosis of cNET or ACC does not warrant a malignancy diagnosis, but surgery is recommended in surgically fit patients. Due to a recommendation of identical treatment to malignant and mucinous high-risk cysts, for the purpose of analysis in this study, each one of these diagnoses was classified as a high-risk cyst.

***Data extraction***

After study selection, two authors (SF and AL) extracted and registered the data from each study onto a standardized worksheet. Disagreements were discussed and reviewed by a third author (LP). The data retrieved were: first author, publication year, study period and design (prospective or retrospective), reference for diagnosis, sample size (all patients included in the study), technical success, adverse events, diagnostic yield, surgical cohort (number of patients with a surgical pathology specimen), cyst size, cyst location, specific cyst types, number of high-risk cysts, mucinous low-risk and benign cysts diagnosed by MA and MFB comparing to surgical pathology specimens. In the MFB studies, technical success was defined as the ability to puncture the cysts and perform the biopsies; and the diagnostic yield was defined as the ratio between the number of patients included in the study and the patients in whom enough material allowed the acquisition of a histopathologic diagnosis. In the MA group, diagnostic yield was defined as a ratio between the number of patients included in the study and the number of patients with DNA available to perform molecular analysis in PCF.

***Outcomes***

The primary outcomes of this study were the data to obtain the accuracies of MA and MFB for the diagnosis of PCNs, including high-risk cysts, mucinous low-risk cysts, and benign cysts. Secondary outcomes were the diagnostic yield of genetic testing and MFB and the number of cysts correctly identified for each of the tests studied.

***Quality analysis***

Methodological quality of included primary studies was assessed by two authors (SF and AL) using the modified QUADAS-2 tool[23]. The PRISMA-DTA Statement recommendations were used for reporting this systematic review[22,24].

***Statistical analysis and data synthesis***

The reference standard was a surgical pathology specimen that allowed the classification of PCNs into three defined groups of diagnosis: high-risk cysts, mucinous low-risk cysts, and benign cysts. This resulted in a two-by-three table with correct and incorrect test results in each of the three referenced groups, for each of the tests analyzed, MA and histology were obtained by MFB.

To calculate tests’ accuracy and to reflect on the categories that are useful in clinical practice and that guide management, we constructed two-by-two tables, considering three definitions of “relevant” cysts: (1) High-risk cysts – proven malignant cysts, IPMNs, and MCNs with HGA, cNETs, ACCs; Non-High-risk cysts – all cysts except those proven to be high-risk. (2) Low-risk mucinous cysts – proven mucinous low-risk cysts; High-risk cysts – all except those proven to be mucinous low-risk or benign. And (3) Non-benign cysts – all cysts except those proven to be benign; Benign cysts – proven benign cysts.

The ability of the tests to discriminate “relevant” and “non-relevant” cysts using the three definitions of “relevant cysts” was evaluated and the accuracy of the two tests was compared.

The data of the two-by-two tables were used to calculate sensitivity and specificity for each study. We present individual study results graphically by plotting the estimates of sensitivity and specificity (and their 95% confidence intervals (CI)) in both forest plots and on the summary receiver operating characteristic (sROC) curve plots. The area under the curve (AUC) is equal to 1 for a perfect test and 0.5 for a completely uninformative test. The AUC is equal to the probability that if a pair of relevant and non-relevant cysts is selected at random, the relevant cyst will have a higher test result than the non-relevant cyst. Pooled estimates of the sensitivity and specificity were obtained by the DerSimonian-Laird method (random effect model) to incorporate variation among studies, when data are heterogeneous. Otherwise, we used the Mantel-Haenszel method (fixed effect model).

Heterogeneity was investigated in the first instance through visual examination of forest plots of sensitivities and specificities and through visual examination of the ROC plot of the raw data. Last, we used statistical tests, including chi-square and Cochran-Q to evaluate if the differences across the studies were greater than expected by chance alone. A low p-value suggests presence of heterogeneity. In addition to these statistics we used the statistic I2 of Higgins, which has been proposed as a measure to quantify the amount of heterogeneity[25,26]. The scale of *I2* has a range of 0 to 100% and values on the order of 25%, 50% and 75% are considered low, moderate, and high heterogeneity, respectively.

Another goal of this work was to obtain, for each of the tests, the correctly identified cyst rate and the diagnostic yield in predicting a histopathologic diagnosis.

We used Comprehensive Meta-Analysis software (Version 2.0) for assessment of diagnostic yield of the tests and Meta-DiSc (version 1.4 – Meta-Analysis of Diagnostic and screening tests[27] ) to obtain the accuracy of each of the tests.

**RESULTS**

***Systematic Review***

Our search revealed 16 study titles and abstracts for MFB and 264 titles for MA. In Figure 1A and B are described the selection process of the articles included in this study. After all steps, eight studies were considered suitable for qualitative and seven for quantitative analysis. We excluded 20 full-text articles after review, because they were case series of two patients[16] (*n* = 1), exploratory or pilot studies[28,29] (*n* = 2), no information of mutation status was available[30] (*n* = 1), pancreatic cystic fluid was obtained during surgery[31] (*n* = 1), insufficient or absent data of cysts with surgical pathology diagnoses[12,32,33] (*n* = 3), and mutations only of *KRAS* and/or *GNAS*[14,34-44] (*n* = 12).

Of the eight studies that met the inclusion criteria, design was retrospective in six and prospective in two, all were published from 2015 to 2018. These eight studies included a total of 1206 patients, of which 203 (17%) underwent surgical resection and a surgical pathology specimen was available as reference standard and included in the analysis. We excluded all patients with cytology and clinical follow-up data, but for whom a surgical pathology specimen was not available. The characteristics of the studies, surgical pathology diagnoses, and MA and MFB results are presented in Tables 1[32,45-47] and 2[18-21].

**Quality assessment and publication bias:** Methodological quality of primary studies included was assessed by two authors (SF and AL) using the modified QUADAS-2 tool[23], which evaluates the quality of articles for systematic reviews of diagnostic accuracy studies in four domains, including patient selection, index test, reference standard, and flow and timing, for risk of bias and applicability concerns. Results are presented in Figure 2, which was sketched with templates available at www.quadas.org. The studies included in this review all showed a “low-risk” classification as the index tests (MA and MFB) and the reference standard (surgical pathology specimen) were reliable and mentioned in all studies. However, a “high-risk” of selection bias was demonstrated in patient selection (neither random nor sequential patients included in several studies) and in flow and timing because only a small proportion of the patients evaluated in all studies, except one, were included in the analysis. In fact, most patients were excluded in all studies as the inclusion criteria requiring surgical pathology as diagnostic reference were not met. Applicability concerns in patient selection were also significant in all studies, because the subgroup of PCNs referred for surgery is more often malignant than PCNs on surveillance, which would also be targeted with this review. Because of this bias, there may be an overestimation of both the sensitivity of the index tests, due to a more severe spectrum of PCNs that are referred for surgery, and the positive predictive value (PPV) for diagnosis of high-risk cysts, due to an increased prevalence of malignant cysts in a surgical cohort of PCNs.

***Meta-analysis***

**Molecular analysis:** Four articles were included in the meta-analysis for diagnostic accuracy of MA. For each of the three definitions of relevant cyst, forest plots of sensitivity and specificity with heterogeneous denoted are shown in Figure 3.

The three criteria to define “relevant cysts” resulted in a different range of the specificity and sensitivity of the studies included as shown in Figure 3. For diagnosis of the subgroup with high-risk and low-risk mucinous cysts that require intervention (either surgery or surveillance) comparing to benign cysts the pooled sensitivity was 0.75 (95%CI: 0.66-0.83) and the pooled specificity was 0.72 (95%CI: 0.56-0.85) for MA. In the subgroup of high-risk cysts that require surgery, comparing to other cysts requiring conservative management, the sensitivity was 0.57 (95%CI: 0.42-0.71) with a specificity of 0.88 (95%CI: 0.80-0.93). In the subgroup of low-risk mucinous cysts comparing to high-risk, the pooled sensitivity was 0.89 (95%CI: 0.79-0.95) and the pooled specificity was 0.88 (95%CI: 0.75-0.95).

Figure 4 displays the sROC curves of MA, showing the sensitivity of the individual articles mapped on the vertical scale, 1-specificity on the horizontal scale, with the summary (sensitivity, 1-specificity) point marked, as well as the summary ROC curve and the confidence region for the summary (sensitivity, 1-specificity) points. The area under the sROC curve was 0.7706 (SE: 0.0927) in non-benign cysts, 0.9248 (SE: 0.0691) in high-risk cysts, and 0.9555 (SE: 0.0293) in mucinous low-risk cysts. The results of the studies had greater variation in non-benign cysts as shown by the wide confidence region.

In the four studies, 566 patients had DNA available to perform MA in PCF. Pooled analysis (Figure 5) showed a diagnostic yield of 54.3% (95%CI: 49.8%-58.7%; *I2*= 39.605%; test for heterogeneity *p* = 0.174).

By considering the classification of cysts by specific type (IPMNs, MCNs, cNETs, SCAs, pseudocysts, ACCs, and other RCs), MA identified correctly 73.1% of cysts (95%CI: 61.6%-82.2%; *I2*= 37.381%; test for heterogeneity *p* = 0.203) (Figure 5).

**Micro forceps biopsy:** Four articles were included in the meta-analysis for diagnostic accuracy of histology obtained using MFB. Figure 6 shows the forest plots of sensitivity and specificity for the three subgroups of relevant cysts. The forest plots for MFB show variable specificities within the papers, from 0 to 1, which can be due to the small numbers of patients with the target condition in some studies.

For each of the three subgroups there exists a low heterogeneity in sensitivity (*I2*= 0%, *I2* = 21.4%, *I2* = 0%) and specificity (*I2* = 0%, *I2* = 0%, *I2* = 21.4%), therefore fixed effect models were used. As presented in Figure 6, in the first subgroup the pooled sensitivity was 0.73 (95%CI: 0.50-0.89) and the pooled specificity was 0.88 (95%CI: 0.28-1.00). In the second subgroup sensitivity was 0.81 (95%CI: 0.46-0.98) with a specificity of 0.77 (95%CI: 0.50-0.94) and in the last subgroup the pooled sensitivity was 0.64 (95%CI: 0.33-0.88) and the pooled specificity was 0.81 (95%CI: 0.46-0.98).

The results were plotted as a symmetrical sROC curve (Figure 4). The area under the sROC curve was 0.7640 (SE: 0.1261) in the first subgroup, 0.8154 (SE: 0.098) in the second subgroup, and 0.7509 (SE: 0.1277) in the last subgroup.

By pooling the data of the four studies that investigated the use of MFB to obtain a histopathologic diagnosis, we obtained a diagnostic yield of 73.1% (95%CI: 61.4%-82.2%; *I2* = 47.774%; test for heterogeneity *p* = 0.125) (Figure 5).

By considering the outcome “specific cyst type” diagnosis, MFB correctly identified 70.7% of the cysts (95%CI: 49.4%-85.6%; *I2* = 0%; test for heterogeneity *p* = 0.056) (Figure 5).

**DISCUSSION**

In this meta-analysis we analyzed two different but promising tests to diagnose PCNs – molecular analysis and microforceps biopsy. To our knowledge this is the first study of this nature, and it included 1206 patients with PCNs of which 1058 underwent MA and 148 MFB. All patients had the index tests performed in PCF obtained pre-operatively, exclusively with NGS for MA and the Moray micro forceps biopsy device (US Endoscopy, Mentor, Ohio) used for MFB. We analyzed 203 cysts, 178 evaluated with MA and 25 with MFB, all referred for surgery, and with a surgical pathology specimen used as reference standard for diagnosis.

In this comparative analysis we included all studies, without restriction to simultaneous evaluation of both tests, because only one of such studies has been published[20]. This study, which includes 48 patients but only 10 surgical pathology specimens, showed identical results for MA and MFB in low-risk and high-risk cyst diagnosis, but higher specific cyst type diagnosis for MFB.

The data from the seven studies included in the meta-analysis, although with limited number of patients, particularly for MFB, suggests that MA is more accurate than MFB for diagnosis of PCNs, including high-risk and low-risk lesions. MA has superior accuracy to discriminate high-risk cysts from other PCNs and low-risk from high-risk neoplastic cysts. MA performance was considered excellent with AUC values of 0.92 and of 0.96 for high-risk and low-risk neoplastic lesions, respectively, as compared to MFB, which showed a fair or good performance, with an AUC of 0.81 and 0.75, respectively for the same lesions (Figure 4). The specificity of MA is good (0.88) but it has a low sensitivity (only 0.57) for high-risk cysts. This may be explained by technical issues, by low prevalence of relevant genetic mutations in malignant PCNs, or by mutations not included in the current NGS panels. The sensitivity and specificity are high (0.89 and 0.88, respectively) for MA when comparing low-risk to high-risk cysts, which reflects the genetic nature of pancreatic carcinogenesis with cumulative mutations from benign to malignant cysts[48].

For discriminating benign cysts from both low-risk and high-risk cysts, the performance of MA and MFB was identical and fair according to AUC values of 0.77 and 0.76, respectively. This non-superiority of MA in the diagnosis of benign cysts in this meta-analysis may be due to technique-inherent issues and/or under-representation of benign cysts in surgical series. In fact, “no genetic mutation” is considered a false negative result in most benign rare cysts, but some of these lesions (retention cysts, etc.) have no diagnostic genetic mutations. On the contrary, the most frequent benign cysts, SCAs, harbor a VHL mutation, exclusively present in these benign lesions and allowing for discarding a malignant lesion. In the MA studies, one third of rare benign cysts were classified as false negative results, due to absence of characteristic mutations (Table 1). Another example of PCN that is not amenable to a MA diagnosis with current genetic panels is cNET, also reducing the accuracy of MA for diagnosis of high-risk cysts. The sensitivities were identical for MA and MFB (0.75 and 0.72), but the latter had higher specificity (0.73 and 0.88, respectively). Limited tissue sampling with MFB can explain the reduced sensitivity with robust specificity. As MA depends on denuded DNA in suspension in PCF, no sampling error is expected, which may explain its greater accuracy in neoplastic cysts, comparing to MFB.

Concerning secondary outcomes, even with the limitations of tissue sampling inherent to MFB, this meta-analysis showed that the diagnostic yield of MFB was superior to MA with rates of correctly identified cyst identical with MA and MFB (Tables 1 and 2). In fact, the definition of diagnostic yield, which for MA was “detection of genetic mutations”, may have led to a falsely low value due to the presence of some rare types of benign cysts (retention cysts, lymphoepithelial cysts, epidermoid cysts, squamous cysts in two studies[46,47]) that have no characteristic diagnostic genetic mutations.

In clinical practice, patient symptoms, cyst imaging features, CEA, and cytology of PCF are required for diagnosis and decision for either treatment or surveillance according to cyst types[49]. PCF analysis, including CEA to distinguish mucinous from non-mucinous cysts and cytology to select those that harbor HGA or early pancreatic carcinoma and require surgical treatment, have suboptimal accuracies[3], due to scant cellularity and limited PCF volume. In this context, additional diagnostic tests are necessary to improve cyst classification and refine clinical decision. DNA markers require limited amounts of PCF, increasing the diagnostic yield[32,45,50,51], but with considerable technical complexity and costs. In fact, in routine clinical practice a major pitfall for PCNs diagnosis is the limited volume of PCF obtained, precluding routine pre-operative testing. As DNA analysis requires less volume of PCF, it may become an alternative test in these circumstances. This major advantage of molecular analysis was not possible to evaluate in this meta-analysis, because the volume of cystic fluid obtained in pancreatic cysts was not available in most studies analyzed.

As MA continues to evolve, questions remain about its accuracy, how it influences patient management, and in what order the analysis should be performed to better support clinical decisions. Previous studies[49]  have shown that DNA testing combined with clinical features increased PCNs diagnosis compared to either alone. With multiple recent advances in biomarkers, molecular genetics will probably prove to be useful in the management of PCNs[52]. In a previous meta-analysis, pre-operative cytology of PCNs has shown low sensitivity for diagnosis[53], endorsing additional tests to improve diagnosis. Another meta-analysis of diagnostic accuracy of EUS-FNA with CEA and cytology analysis in differentiating mucinous cysts has demonstrated to be accurate to confirm the diagnosis but performed poorly in excluding it[54]. The role of *KRAS* as individual screening test has been analyzed before[55] with poor accuracy and added benefit coming from a combined approach with cytology. A recently published meta-analysis supporting *KRAS, GNAS,* and *RNF43* mutations as diagnostic markers of IPMNs[56]  used different methods for mutation detection, different tumor materials, and clinicopathologic data as reference standard for diagnosis, which may limit its clinical application in evaluation of PCNs with mutational analysis performed only in PCF.

In this scenario, new markers are needed for PCNs stratification, and in our meta-analysis both MA and MFB have acceptable diagnostic accuracies. The two largest studies of MA[46,47]  showed higher accuracy for diagnosis, which underscores the role of technical aspects of PCF collection, storage, and laboratory analysis for improved accuracy with this technique.

On the other hand, MFB provides tissue fragments for routine histological evaluation, without additional PCF required other than for standard analysis. The technical feasibility of through-the-needle microforceps biopsies revealed to be excellent, even in cysts located in the pancreatic head, despite the required 19-gauge caliber of the EUS-FNA needle. Another potential advantage of MFB is to allow the diagnosis of histologic subtypes of IPMNs, which can potentially be used for risk stratification[57], but still requires further validation.

***Strengths and limitations***

We applied strict exclusion criteria, with all analyzed patients having a surgical pathology specimen as the reference standard for diagnosis, because histopathology is the gold standard for diagnosis of neoplasia. Another major strength of this meta-analysis is having identical lesions (size and location) analyzed in both groups. These important strengths provide a more realistic accuracy estimate of the tests evaluated. In previous studies of cytology including both surgical pathology and clinical follow-up[54]  as reference standard, pooled sensitivities were 12% higher than in studies with exclusive surgical pathology[55]  as reference standard in the diagnosis of mucinous cysts, with test accuracy overestimation. Finally, the pooled results have low heterogeneity.

The quality of a systematic review depends on the quality of studies included, and our quality assessment of patient selection regarding the risk of bias and applicability was high. As sensitivity and specificity are sensitive to study design and influenced by the spectrum of disease, sample collection, and processing, there may be a risk of bias and the results, although correct, their interpretation may be inaccurate. Moreover, there was incomplete reporting in one primary study, having no separate information on specific cyst type, mucinous or malignant cyst diagnosis[32], and the study was excluded from quantitative analysis. Although one study was excluded from the meta-analysis, MA with three studies included more patients (953, of whom only 153 in the surgical cohort) than the group of MFB with four studies but fewer patients (148, with only 25 in the surgical cohort). This can represent a surgical selection bias for both tests studied. Moreover, MFB studies were all retrospective, with small sample size, without pathology diagnosis for most benign and pre-malignant cysts, and non-consecutive patients that were selected on endoscopist discretion, which may have led to bias. Another limitation is the time between the index tests and the reference standard, because the final diagnosis could have been made at different time intervals from the tests. If the time between index tests and reference standard is too long, the true disease status of the patient may have changed by the time the reference standard was assessed. Aditionally, the different number of malignant cysts per study, particularly in the MA group, may have led to part of the heterogeneity in sensitivity and specificity. Finally, as MA does not increase the risks of standard EUS-FNA (the analysis is performed in remnant cystic fluid after standard diagnosis) we did not perform a safety analysis of MFB, but the four studies analyzed described only rare non-severe adverse events.

***Future perspectives***

With the increasing diagnosis of asymptomatic PCNs, most with potential for malignancy, there is a growing need to find accurate and affordable tests for diagnosis. The goal of management of patients with pancreatic cysts is to detect and resect cysts before progression of malignancy, while avoiding unnecessary follow-up procedures in benign cysts and surgery in low-risk PCNs.

Biomarkers of malignancy are promising, but clinicians should be aware of their current diagnostic performance limitations and type of lesions identified. In addition to significant costs, logistic difficulties in preserving material for future molecular analysis in busy general hospitals, and the technical complexity of the test, the generalized use of MA seems difficult in clinical practice. On the other hand, if MFB proves in larger studies to be safe and to allow tissue acquisition and gives the histological criteria needed for a correct diagnosis of PCNs, it may be immediately implemented in clinics, because the endoscopic procedure is standard, and histology is already a widespread procedure in clinics. MFB may be especially useful for benign lesions, for which both surgery and surveillance are unnecessary, representing a considerable burden in pancreas clinics due to current diagnostic limitations[58].

For MA to become relevant in routine clinical care in the future, its role in early cancer diagnosis and its prognostic value in PCNs requiring periodic surveillance must be confirmed. Also, for successful massive implementation, it is required to develop as an universal, highly accurate, first line test with clinical impact in cyst diagnosis, prognosis, and patient management. MA, both in PCF and peripheral blood, for standard analysis of multiple simultaneous biomarkers, allowing non-invasive diagnosis and risk stratification of these lesions[59]  would be valuable. For the present time, MA and MFB can only be recommended as complementary or as second line tests in case CEA and cytology of PCF are non-diagnostic. For both tests, large multicenter validation studies are still missing.

**CONCLUSION**

Our study confirms the diagnostic value of both MA and MFB, with higher diagnostic accuracy of MA than MFB for both low-risk and high-risk mucinous cysts. Genetic analysis should not be replaced by MFB in this context. Clinicians should be aware of the higher accuracy of MA for the diagnosis of malignant and high-risk cysts.

**ARTICLE HIGHLIGHTS**

***Research background***

Carcinoembryonic antigen (CEA) and cytology of pancreatic cystic fluid (PCF) obtained pre-operatively with endoscopic ultrasound with fine-needle aspiration (EUS-FNA) are suboptimal for diagnostic evaluation of pancreatic cystic neoplasms. Genetic testing of PCF and microforceps biopsy obtained by EUS-FNA are promising tools for pre-operative diagnostic improvement. The comparative performance of both methods has not been previously studied.

***Research motivation***

In the last decade numerous studies have shown that genetic analysis of aspirates obtained by EUS-FNA provided a better characterization of pancreatic cysts than standard CEA and cytology. Next-generation sequencing (NGS) is a very sensitive technique for detection of genetic mutations in pre-defined panels of cancer genes, even in samples with limited DNA content, such as PCF. NGS requires storage, infrastructure, data processing, expert personnel, and large numbers of samples need to be cost-effective. These reasons make the implementation of NGS in clinical practice still a matter of debate. The clinical need of better diagnostic tests in pancreatic cysts led to the development of a through-the-needle miniature biopsy device for use during EUS-FNA. The Moray micro forceps biopsy device (US Endoscopy, Mentor, Ohio) is disposable and can pass through a standard 19-gauge EUS-FNA needle that is already used routinely. It allows tissue sampling from the cyst wall, septa or mural nodules and the obtention of a histological evaluation of the epithelial architecture and subepithelial stroma, with improved pancreatic cyst diagnosis.

***Research objectives***

To compare the diagnostic accuracy of genetic testing and microforceps in the diagnosis of pancreatic cystic neoplasms referred for surgery.

***Research methods***

We performed a literature search in Medline, Scopus, and Web of Science for studies evaluating genetic testing of cystic fluid and microforceps biopsy of pancreatic cysts, with EUS-FNA prior to surgery. We used surgical pathology as reference standard for diagnosis. We evaluated the diagnostic accuracy for: benign cysts; mucinous low-risk cysts; high-risk cysts; the diagnostic yield; and rate of correctly identified cysts with microforceps biopsy and molecular analysis.

***Research results***

Eight studies, including 1206 patients, of which 203 (17%) referred for surgery who met the inclusion criteria were analyzed in the systematic review, and seven studies were included in the meta-analysis. Genetic testing and microforceps biopsies were identical for diagnosis of benign cysts. Molecular analysis was superior for diagnosis of both low and high-risk mucinous cysts. The diagnostic yield was higher in microforceps biopsies than in genetic analysis, but the rates of correctly identified cyst types were identical.

***Research conclusions***

This study underlines the diagnostic value of both MA and MFB, with higher diagnostic accuracy of MA than MFB for both low-risk and high-risk mucinous cysts. Genetic analysis should not be replaced by MFB in this context. However, MA has higher accuracy in the diagnosis of malignant and high-risk cysts.

***Research perspectives***

For the present time, MA and MFB can only be recommended as complementary or as second line tests in case CEA and cytology of PCF are non-diagnostic. In the future, for MA to become relevant in routine clinical care, its role must be confirmed, in order to become a first line test with clinical impact in cyst diagnosis, prognosis, and patient management. MA, both in PCF and peripheral blood, for multiple simultaneous biomarkers and non-invasive diagnosis and risk stratification would be valuable. If MFB proves in larger studies to be safe and to allow a correct diagnosis of pancreatic cysts, it may be immediately implemented in clinics. MFB may be especially useful for benign lesions, for which both surgery and surveillance are unnecessary, with uncertain diagnosis due to current diagnostic limitations. For both tests, larger validation studies are missing.

**REFERENCES**

1 **Stark A**, Donahue TR, Reber HA, Hines OJ. Pancreatic Cyst Disease: A Review. *JAMA* 2016; **315**: 1882-1893 [PMID: 27139061 DOI: 10.1001/jama.2016.4690]

2 **Cizginer S**, Turner BG, Bilge AR, Karaca C, Pitman MB, Brugge WR. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. *Pancreas* 2011; **40**: 1024-1028 [PMID: 21775920 DOI: 10.1097/MPA.0b013e31821bd62f]

3 **Gaddam S**, Ge PS, Keach JW, Mullady D, Fukami N, Edmundowicz SA, Azar RR, Shah RJ, Murad FM, Kushnir VM, Watson RR, Ghassemi KF, Sedarat A, Komanduri S, Jaiyeola DM, Brauer BC, Yen RD, Amateau SK, Hosford L, Hollander T, Donahue TR, Schulick RD, Edil BH, McCarter M, Gajdos C, Attwell A, Muthusamy VR, Early DS, Wani S. Suboptimal accuracy of carcinoembryonic antigen in differentiation of mucinous and nonmucinous pancreatic cysts: results of a large multicenter study. *Gastrointest Endosc* 2015; **82**: 1060-1069 [PMID: 26077458 DOI: 10.1016/j.gie.2015.04.040]

4 **Correa-Gallego C**, Ferrone CR, Thayer SP, Wargo JA, Warshaw AL, Fernández-Del Castillo C. Incidental pancreatic cysts: do we really know what we are watching? *Pancreatology* 2010; **10**: 144-150 [PMID: 20484954 DOI: 10.1159/000243733]

5 **Cho CS**, Russ AJ, Loeffler AG, Rettammel RJ, Oudheusden G, Winslow ER, Weber SM. Preoperative classification of pancreatic cystic neoplasms: the clinical significance of diagnostic inaccuracy. *Ann Surg Oncol* 2013; **20**: 3112-3119 [PMID: 23595223 DOI: 10.1245/s10434-013-2986-6]

6 **Khalid A**, McGrath KM, Zahid M, Wilson M, Brody D, Swalsky P, Moser AJ, Lee KK, Slivka A, Whitcomb DC, Finkelstein S. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. *Clin Gastroenterol Hepatol* 2005; **3**: 967-973 [PMID: 16234041 DOI: 10.1016/S1542-3565(05)00409-X]

7 **Schoedel KE**, Finkelstein SD, Ohori NP. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. *Diagn Cytopathol* 2006; **34**: 605-608 [PMID: 16900481 DOI: 10.1002/dc.20511]

8 **Sreenarasimhaiah J**, Lara LF, Jazrawi SF, Barnett CC, Tang SJ. A comparative analysis of pancreas cyst fluid CEA and histology with DNA mutational analysis in the detection of mucin producing or malignant cysts. *JOP* 2009; **10**: 163-168 [PMID: 19287110]

9 **Shen J**, Brugge WR, Dimaio CJ, Pitman MB. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. *Cancer* 2009; **117**: 217-227 [PMID: 19415731 DOI: 10.1002/cncy.20027]

10 **Sawhney MS**, Devarajan S, O'Farrel P, Cury MS, Kundu R, Vollmer CM, Brown A, Chuttani R, Pleskow DK. Comparison of carcinoembryonic antigen and molecular analysis in pancreatic cyst fluid. *Gastrointest Endosc* 2009; **69**: 1106-1110 [PMID: 19249035 DOI: 10.1016/j.gie.2008.08.015]

11 **Khalid A**, Zahid M, Finkelstein SD, LeBlanc JK, Kaushik N, Ahmad N, Brugge WR, Edmundowicz SA, Hawes RH, McGrath KM. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. *Gastrointest Endosc* 2009; **69**: 1095-1102 [PMID: 19152896 DOI: 10.1016/j.gie.2008.07.033]

12 **Talar-Wojnarowska R**, Pazurek M, Durko L, Degowska M, Rydzewska G, Smigielski J, Janiak A, Olakowski M, Lampe P, Grzelak P, Stefanczyk L, Smolarz B, Malecka-Panas E. A comparative analysis of K-ras mutation and carcinoembryonic antigen in pancreatic cyst fluid. *Pancreatology* 2012; **12**: 417-420 [PMID: 23127529 DOI: 10.1016/j.pan.2012.08.001]

13 **Chai SM**, Herba K, Kumarasinghe MP, de Boer WB, Amanuel B, Grieu-Iacopetta F, Lim EM, Segarajasingam D, Yusoff I, Choo C, Frost F. Optimizing the multimodal approach to pancreatic cyst fluid diagnosis: developing a volume-based triage protocol. *Cancer Cytopathol* 2013; **121**: 86-100 [PMID: 22961878 DOI: 10.1002/cncy.21226]

14 **Mertz H**. K-ras mutations correlate with atypical cytology and elevated CEA levels in pancreatic cystic neoplasms. *Dig Dis Sci* 2011; **56**: 2197-2201 [PMID: 21264513 DOI: 10.1007/s10620-010-1556-z]

15 **Barresi L**, Tarantino I, Ligresti D, Curcio G, Granata A, Traina M. A new tissue acquisition technique in pancreatic cystic neoplasm: endoscopic ultrasound-guided through-the-needle forceps biopsy. *Endoscopy* 2015; **47 Suppl 1 UCTN**: E297-E298 [PMID: 26099102 DOI: 10.1055/s-0034-1392031]

16 **Shakhatreh MH**, Naini SR, Brijbassie AA, Grider DJ, Shen P, Yeaton P. Use of a novel through-the-needle biopsy forceps in endoscopic ultrasound. *Endosc Int Open* 2016; **4**: E439-E442 [PMID: 27092324 DOI: 10.1055/s-0042-101941]

17 **Crinò SF**, Bernardoni L, Gabbrielli A, Capelli P, Salvia R, Rusev BC, Scarpa A, Manfrin E. Beyond Pancreatic Cyst Epithelium: Evidence of Ovarian-Like Stroma in EUS-Guided Through-the-Needle Micro-Forceps Biopsy Specimens. *Am J Gastroenterol* 2018; **113**: 1059-1060 [PMID: 29899433 DOI: 10.1038/s41395-018-0124-6]

18 **Mittal C**, Obuch JC, Hammad H, Edmundowicz SA, Wani S, Shah RJ, Brauer BC, Attwell AR, Kaplan JB, Wagh MS. Technical feasibility, diagnostic yield, and safety of microforceps biopsies during EUS evaluation of pancreatic cystic lesions (with video). *Gastrointest Endosc* 2018; **87**: 1263-1269 [PMID: 29309781 DOI: 10.1016/j.gie.2017.12.025]

19 **Kovacevic B**, Klausen P, Hasselby JP, Karstensen JG, Rift CV, Kalaitzakis E, Toxværd A, Hansen CP, Storkholm J, Hassan H, Vilmann P. A novel endoscopic ultrasound-guided through-the-needle microbiopsy procedure improves diagnosis of pancreatic cystic lesions. *Endoscopy* 2018; **50**: 1105-1111 [PMID: 29980151 DOI: 10.1055/a-0625-6440]

20 **Zhang ML**, Arpin RN, Brugge WR, Forcione DG, Basar O, Pitman MB. Moray micro forceps biopsy improves the diagnosis of specific pancreatic cysts. *Cancer Cytopathol* 2018; **126**: 414-420 [PMID: 29660844 DOI: 10.1002/cncy.21988]

21 **Basar O**, Yuksel O, Yang DJ, Samarasena J, Forcione D, DiMaio CJ, Wagh MS, Chang K, Casey B, Fernandez-Del Castillo C, Pitman MB, Brugge WR. Feasibility and safety of microforceps biopsy in the diagnosis of pancreatic cysts. *Gastrointest Endosc* 2018; **88**: 79-86 [PMID: 29510146 DOI: 10.1016/j.gie.2018.02.039]

22 **McInnes MDF**, Moher D, Thombs BD, McGrath TA, Bossuyt PM; the PRISMA-DTA Group, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. *JAMA* 2018; **319**: 388-396 [PMID: 29362800 DOI: 10.1001/jama.2017.19163]

23 **Whiting PF**, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011; **155**: 529-536 [PMID: 22007046 DOI: 10.7326/0003-4819-155-8-201110180-00009]

24 **Moher D**, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015; **4**: 1 [PMID: 25554246 DOI: 10.1186/2046-4053-4-1]

25 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

26 **Higgins JP**, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**: 1539-1558 [PMID: 12111919 DOI: 10.1002/sim.1186]

27 **Zamora J**, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. *BMC Med Res Methodol* 2006; **6**: 31 [PMID: 16836745 DOI: 10.1186/1471-2288-6-31]

28 **Siddiqui AA**, Kowalski TE, Kedika R, Roy A, Loren DE, Ellsworth E, Adler D, Finkelstein SD. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study. *Gastrointest Endosc* 2013; **77**: 669-670 [PMID: 23498145 DOI: 10.1016/j.gie.2012.11.009]

29 **Wu J**, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, Schmidt CM, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Sci Transl Med* 2011; **3**: 92ra66 [PMID: 21775669 DOI: 10.1126/scitranslmed.3002543]

30 **Al-Haddad MA**, Kowalski T, Siddiqui A, Mertz HR, Mallat D, Haddad N, Malhotra N, Sadowski B, Lybik MJ, Patel SN, Okoh E, Rosenkranz L, Karasik M, Golioto M, Linder J, Catalano MF. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. *Endoscopy* 2015; **47**: 136-142 [PMID: 25314329 DOI: 10.1055/s-0034-1390742]

31 **Amato E**, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, Fassan M, Antonello D, Sadakari Y, Castelli P, Zamboni G, Maitra A, Salvia R, Hruban RH, Bassi C, Capelli P, Lawlor RT, Goggins M, Scarpa A. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. *J Pathol* 2014; **233**: 217-227 [PMID: 24604757 DOI: 10.1002/path.4344]

32 **Rosenbaum MW**, Jones M, Dudley JC, Le LP, Iafrate AJ, Pitman MB. Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts. *Cancer Cytopathol* 2017; **125**: 41-47 [PMID: 27647802 DOI: 10.1002/cncy.21775]

33 **Kadayifci A**, Atar M, Wang JL, Forcione DG, Casey BW, Pitman MB, Brugge WR. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms. *Dig Endosc* 2017; **29**: 111-117 [PMID: 27514845 DOI: 10.1111/den.12710]

34 **Toll AD**, Kowalski T, Loren D, Bibbo M. The added value of molecular testing in small pancreatic cysts. *JOP* 2010; **11**: 582-586 [PMID: 21068490]

35 **Panarelli NC**, Sela R, Schreiner AM, Crapanzano JP, Klimstra DS, Schnoll-Sussman F, Pochapin MB, Yantiss RK. Commercial molecular panels are of limited utility in the classification of pancreatic cystic lesions. *Am J Surg Pathol* 2012; **36**: 1434-1443 [PMID: 22982886 DOI: 10.1097/PAS.0b013e31825d534a]

36 **Rockacy MJ**, Zahid M, McGrath KM, Fasanella KE, Khalid A. Association between KRAS mutation, detected in pancreatic cyst fluid, and long-term outcomes of patients. *Clin Gastroenterol Hepatol* 2013; **11**: 425-429 [PMID: 23267865 DOI: 10.1016/j.cgh.2012.12.008]

37 **Nikiforova MN**, Khalid A, Fasanella KE, McGrath KM, Brand RE, Chennat JS, Slivka A, Zeh HJ, Zureikat AH, Krasinskas AM, Ohori NP, Schoedel KE, Navina S, Mantha GS, Pai RK, Singhi AD. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. *Mod Pathol* 2013; **26**: 1478-1487 [PMID: 23743931 DOI: 10.1038/modpathol.2013.91]

38 **Al-Haddad M**, DeWitt J, Sherman S, Schmidt CM, LeBlanc JK, McHenry L, Coté G, El Chafic AH, Luz L, Stuart JS, Johnson CS, Klochan C, Imperiale TF. Performance characteristics of molecular (DNA) analysis for the diagnosis of mucinous pancreatic cysts. *Gastrointest Endosc* 2014; **79**: 79-87 [PMID: 23845445 DOI: 10.1016/j.gie.2013.05.026]

39 **Singhi AD**, Nikiforova MN, Fasanella KE, McGrath KM, Pai RK, Ohori NP, Bartholow TL, Brand RE, Chennat JS, Lu X, Papachristou GI, Slivka A, Zeh HJ, Zureikat AH, Lee KK, Tsung A, Mantha GS, Khalid A. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. *Clin Cancer Res* 2014; **20**: 4381-4389 [PMID: 24938521 DOI: 10.1158/1078-0432.CCR-14-0513]

40 **Kung JS**, Lopez OA, McCoy EE, Reicher S, Eysselein VE. Fluid genetic analyses predict the biological behavior of pancreatic cysts: three-year experience. *JOP* 2014; **15**: 427-432 [PMID: 25262708 DOI: 10.6092/1590-8577/2426]

41 **Winner M**, Sethi A, Poneros JM, Stavropoulos SN, Francisco P, Lightdale CJ, Allendorf JD, Stevens PD, Gonda TA. The role of molecular analysis in the diagnosis and surveillance of pancreatic cystic neoplasms. *JOP* 2015; **16**: 143-149 [PMID: 25791547 DOI: 10.6092/1590-8577/2941]

42 **Kadayifci A**, Al-Haddad M, Atar M, Dewitt JM, Forcione DG, Sherman S, Casey BW, Fernandez-Del Castillo C, Schmidt CM, Pitman MB, Brugge WR. The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts. *Endosc Int Open* 2016; **4**: E391-E396 [PMID: 27092317 DOI: 10.1055/s-0042-101755]

43 **ASGE Standards of Practice Committee**, Muthusamy VR, Chandrasekhara V, Acosta RD, Bruining DH, Chathadi KV, Eloubeidi MA, Faulx AL, Fonkalsrud L, Gurudu SR, Khashab MA, Kothari S, Lightdale JR, Pasha SF, Saltzman JR, Shaukat A, Wang A, Yang J, Cash BD, DeWitt JM. The role of endoscopy in the diagnosis and treatment of cystic pancreatic neoplasms. *Gastrointest Endosc* 2016; **84**: 1-9 [PMID: 27206409 DOI: 10.1016/j.gie.2016.04.014]

44 **Kowalski T**, Siddiqui A, Loren D, Mertz HR, Mallat D, Haddad N, Malhotra N, Sadowski B, Lybik MJ, Patel SN, Okoh E, Rosenkranz L, Karasik M, Golioto M, Linder J, Catalano MF, Al-Haddad MA. Management of Patients With Pancreatic Cysts: Analysis of Possible False-Negative Cases of Malignancy. *J Clin Gastroenterol* 2016; **50**: 649-657 [PMID: 27332745 DOI: 10.1097/MCG.0000000000000577]

45 **Jones M**, Zheng Z, Wang J, Dudley J, Albanese E, Kadayifci A, Dias-Santagata D, Le L, Brugge WR, Fernandez-del Castillo C, Mino-Kenudson M, Iafrate AJ, Pitman MB. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. *Gastrointest Endosc* 2016; **83**: 140-148 [PMID: 26253016 DOI: 10.1016/j.gie.2015.06.047]

46 **Singhi AD**, Zeh HJ, Brand RE, Nikiforova MN, Chennat JS, Fasanella KE, Khalid A, Papachristou GI, Slivka A, Hogg M, Lee KK, Tsung A, Zureikat AH, McGrath K. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. *Gastrointest Endosc* 2016; **83**: 1107-1117.e2 [PMID: 26709110 DOI: 10.1016/j.gie.2015.12.009]

47 **Singhi AD**, McGrath K, Brand RE, Khalid A, Zeh HJ, Chennat JS, Fasanella KE, Papachristou GI, Slivka A, Bartlett DL, Dasyam AK, Hogg M, Lee KK, Marsh JW, Monaco SE, Ohori NP, Pingpank JF, Tsung A, Zureikat AH, Wald AI, Nikiforova MN. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. *Gut* 2018; **67**: 2131-2141 [PMID: 28970292 DOI: 10.1136/gutjnl-2016-313586]

48 **Felsenstein M**, Hruban RH, Wood LD. New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. *Adv Anat Pathol* 2018; **25**: 131-142 [PMID: 28914620 DOI: 10.1097/PAP.0000000000000172]

49 **Springer S**, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology* 2015; **149**: 1501-1510 [PMID: 26253305 DOI: 10.1053/j.gastro.2015.07.041]

50 **Thiruvengadam N**, Park WG. Systematic Review of Pancreatic Cyst Fluid Biomarkers: The Path Forward. *Clin Transl Gastroenterol* 2015; **6**: e88 [PMID: 26065716 DOI: 10.1038/ctg.2015.17]

51 **Singhi AD**, Nikiforova MN, McGrath K. DNA testing of pancreatic cyst fluid: is it ready for prime time? *Lancet Gastroenterol Hepatol* 2017; **2**: 63-72 [PMID: 28404017 DOI: 10.1016/S2468-1253(16)30084-X]

52 **Kulzer M**, Singhi AD, Furlan A, Heller MT, Katabathina VS, Mcgrath KM, Zeh HJ, Zureikat A, Dasyam AK. Current concepts in molecular genetics and management guidelines for pancreatic cystic neoplasms: an essential update for radiologists. *Abdom Radiol (NY)* 2018; **43**: 2351-2368 [PMID: 29404638 DOI: 10.1007/s00261-017-1452-5]

53 **Thosani N**, Thosani S, Qiao W, Fleming JB, Bhutani MS, Guha S. Role of EUS-FNA-based cytology in the diagnosis of mucinous pancreatic cystic lesions: a systematic review and meta-analysis. *Dig Dis Sci* 2010; **55**: 2756-2766 [PMID: 20694512 DOI: 10.1007/s10620-010-1361-8]

54 **Thornton GD**, McPhail MJ, Nayagam S, Hewitt MJ, Vlavianos P, Monahan KJ. Endoscopic ultrasound guided fine needle aspiration for the diagnosis of pancreatic cystic neoplasms: a meta-analysis. *Pancreatology* 2013; **13**: 48-57 [PMID: 23395570 DOI: 10.1016/j.pan.2012.11.313]

55 **Gillis A**, Cipollone I, Cousins G, Conlon K. Does EUS-FNA molecular analysis carry additional value when compared to cytology in the diagnosis of pancreatic cystic neoplasm? A systematic review. *HPB (Oxford)* 2015; **17**: 377-386 [PMID: 25428782 DOI: 10.1111/hpb.12364]

56 **Lee JH**, Kim Y, Choi JW, Kim YS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. *Springerplus* 2016; **5**: 1172 [PMID: 27512631 DOI: 10.1186/s40064-016-2847-4]

57 **Ishida M**, Egawa S, Aoki T, Sakata N, Mikami Y, Motoi F, Abe T, Fukuyama S, Sunamura M, Unno M, Moriya T, Horii A, Furukawa T. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. *Pancreas* 2007; **35**: 348-352 [PMID: 18090241 DOI: 10.1097/mpa.0b013e31806da090]

58 **Rosenkrantz AB**, Xue X, Gyftopoulos S, Kim DC, Nicola GN. Downstream Costs Associated With Incidental Pancreatic Cysts Detected at MRI. *AJR Am J Roentgenol* 2018; **211**: 1278-1282 [PMID: 30300007 DOI: 10.2214/AJR.18.19885]

59 **de Biase D**, Visani M, Acquaviva G, Fornelli A, Masetti M, Fabbri C, Pession A, Tallini G. The Role of Next-Generation Sequencing in the Cytologic Diagnosis of Pancreatic Lesions. *Arch Pathol Lab Med* 2018; **142**: 458-464 [PMID: 29565213 DOI: 10.5858/arpa.2017-0215-RA]

**P-Reviewer:** Kamimura K, Karstensen JG, Lee HC, Luo HS

**S-Editor:** Gong ZM **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Portugal

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**A**

**Included**

**Eligibility**

**Identification**

**Screening**

Records identified through database searching

(*n* = 264)

Additional records identified through other sources

(*n* = 9)

Records after duplicates removed (*n* = 222)

Records screened (*n* = 222)

Records excluded: other biomarkers, other king of neoplasms, reviews (*n* = 199)

Full-text articles assessed for eligibility (*n* = 23)

Studies included in qualitative synthesis (*n* = 4)

19 of full-text articles excluded, with reasons

studies included in quantitative synthesis (meta-analysis)

(*n* = 3)

**B**

**Included**

**Eligibility**

**Identification**

**Screening**

Records identified through database searching

(*n* = 14)

Additional records identified through other sources

(*n* = 3)

Records after duplicates removed (*n* = 14)

Records screened (*n* = 14)

Records excluded: case reports (*n* = 8), reviews (*n* = 1)

Full-text articles assessed for eligibility (*n* = 5)

Studies included in qualitative synthesis (*n* = 4)

1 of full-text article excluded, with reasons

Studies included in quantitative synthesis (meta-analysis)

(*n* = 4)

**Figure 1 Flowchart with identification of eligible studies.** A: Molecular analysis; B: Microforceps biopsy.

**A**

|  |  |  |
| --- | --- | --- |
| **Study** | **Risk of bias** | **Applicability concerns** |
| **Patient selection** | **Index test** | **Reference standard** | **Flow and timing** | **Patient selection** | **Index test** | **Reference standard** |
| Jones *et al*[45], 2015  | ☺ | ☺ | ☺ | ☹ | ☹ | ☺ | ☺ |
| Singhi *et al*[46], 2016  | ☺ | ☺ | ☺ | ☹ | ☹ | ☺ | ☺ |
| Rosenbaum *et al*[32], 2016  | ☹ | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ |
| Singhi *et al*[47], 2017 | ☺ | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ |
| Mittal *et al*[18], 2018 | ☹ | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ |
| Zhang *et al*[20], 2018 | ☹ | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ |
| Basar *et al*[21], 2018 | ☹ | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ |
| Kovacevic[19], 2018 | ☹ | ☺ | ☺ | ☺ | ☹ | ☺ | ☺ |

☺Low risk; ☹High risk; ? Unclear risk.

**B**



**Figure 2 Quality assessment of the studies using QUADAS-2.** A: Tabular presentation of risk bias for each study; B: Graphical display of bias.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Subgroup** | **Study** | **TP** | **FP** | **FN** | **TN** | **Sensitivity (95% CI)** | **Specificity (95% CI)** | **Sensitivity** | **Specificity** |
|  High risk + Low Risk vs benign | Jones *et al*[45], 2015 | 5 | 0 | 5 | 0 | 0.50 (0.19-0.81) | 0.50 (0.00-1.00) |  C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Sensitiviy MA (HR+LR) versus Benign 3.bmp Pooled Sensitivity = 0.75 (0.66-0.83)Chi-square: 3.59; *P* = 0.1661Inconsistency:  *I2* = 44.3% | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Specificity MA (HR+LR) versus Benign 3.bmp Pooled Specificity = 0.72 (0.56-0.85)Chi-square: 0.23; *P* = 0.8903Inconsistency: *I2*= 0% |
| Singhi *et al*[46], 2016 | 22 | 4 | 5 | 10 | 0.81 (0.62-0.94) | 0.71 (0.42-0.92) |
| Singhi *et al*[47], 2017 | 58 | 7 | 18 | 19 | 0.76 (0.65-0.85) | 0.73 (0.52-0.88) |
|  |
|  High Risk vs Non High Risk | Jones *et al*[45], 2015 | 1 | 0 | 5 | 4 | 0.17 (0.00-0.64) | 1.00 (0.40-1.00) |  C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Sensitivity MA HR versus NHR (Benign+LR) 3.bmpPooled Sensitivity = 0.57 (0.42-0.71)Chi-square: 5.43 P-value= 0.0662Inconsistency: I2=63.2% | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Specificity MA HR versus (Benign+LR) 3.bmpPooled Specificity= 0.88 (0.80-0.93)Chi-square: 1.21 P-value =0.5458Inconsistency: I2=0% |
| Singhi *et al*[46], 2016 | 10 | 3 | 4 | 24 | 0.71 (0.42-0.92) | 0.89 (0.71-0.98) |
| Singhi *et al*[47], 2017 | 17 | 10 | 12 | 63 | 0.59 (0.39-0.76) | 0.86 (0.76-0.93) |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| Low Risk vs High Risk | Jones *et al*[45], 2015 | 4 | 5 | 0 | 1 | 1.00 (0.40-1.00) | 0.17 (0.00-0.64) |  C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Sensitivity MA LR versus HR 3.bmpPooled Sensitivity = 0.89 (0.79-0.95)Chi-square: 1.24; *P* = 0.5391Inconsistency: *I2* = 0% | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Specificity MA LR versus HR 3.bmpPooled Specificity = 0.88 (0.75-0.95)Chi-square: 23.82; *P* < 0.0001Inconsistency:  *I2* = 91.6% |
| Singhi *et al*[46], 2016 | 12 | 1 | 1 | 13 | 0.92 (0.64-1.00) | 0.93 (0.66-1.00) |
| Singhi *et al*[47], 2017 | 41 | 0 | 6 | 29 | 0.87 (0.74-0.95) | 1.00 (0.88-1.00) |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

**Figure 3 Forest plots of the studies included for molecular analysis.** In parentheses are the 95% confidence intervals (CI) of the sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (red circle) and its 95% CI (blue horizontal line). The area of the circle reflects the weight that the study contributes to the meta-analysis.

|  |  |
| --- | --- |
| **Test** | **sROC curves** |
|  | **(High risk + Low risk) *vs* benign** | **High risk *vs* (benign+low risk)** | **Low risk *vs* High risk** |
| **Molecular analysis** | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\SROC MA HR+LR versus Benign 2.bmpSymmetric sROC AUC = 0.7706SE (AUC) = 0.0927 | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\SROC MA HR versus (Benign+LR) 2.bmpSymmetric sROCAUC = 0.9248SE (AUC) = 0.0691 | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\SROC MA LR versus HR 3.bmpSymmetric sROCAUC = 0.9555SE (AUC) = 0.0293 |
| **MicroForceps biopsies** | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\SROC MFB HR+LR versus Benign 2.bmpSymmetric sROCAUC = 0.7640SE (AUC) = 0.1261 | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\SROC MFB HR versus (Benign+LR) 2.bmpSymmetric sROCAUC = 0.8154SE(AUC) = 0.098 | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\SROC MFB LR versus HR 2.bmpSymmetric sROCAUC = 0.7509SE (AUC) = 0.1277 |

**Figure 4 Summary receiver operating characteristics plots.** ROC: Receiver operating characteristic curve; AUC: area under the curve; SE: standard error.

|  |  |
| --- | --- |
| **Molecular Analysis** | **Microforceps Biopsies** |
|  |  |
|  |  |

**Figure 5 Forest plots of molecular analysis and microforceps biopsies on the secondary outcomes of this meta-analysis.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Subgroup** | **Study** | **TP** | **FP** | **FN** | **TN** | **Sensitivity (95% CI)** | **Specificity (95% CI)**  | **Sensitivity** | **Specificity** |
|  High risk + Low Risk vs benign | Mittal *et al*[18], 2018 | 2 | 0 | 2 | 0 | 0.50 (0.07-0.93) | 0.50 (0.00-1.00) |  C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\sensitivity MFB (HR+LR) versus Benign 3.bmp Pooled Sensitivity= 0.73 (0.50-0.89)Chi-square: 1.48 P-value=0.6878Inconsistency: I2=0% | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Specificity MFB (HR+LR) versus Benign 3.bmp Pooled Specificity= 0.88 (0.28-1.00)Chi-square: 1.63 P-value=0.6539Inconsistency: I2=0% |
| Zhang *et al*[20], 2018 | 7 | 0 | 2 | 1 | 0.78 (0.40-0.97)  | 1.00 (0.03-1.00) |
| Basar *et al*[21], 2018 | 5 | 0 | 1 | 1 | 0.83 (0.36-1.00) | 1.00 (0.03-1.00) |
| Kovacevic[19], 2018 | 2 | 0 | 1 | 1 | 0.67 (0.09-0.99) | 1.00 (0.03-1.00) |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  High Risk vs Non High Risk | Mittal *et al*[18], 2018 | 1 | 1 | 0 | 2 | 1.00 (0.03-1.00) | 0.67 (0.09-0.99) |  C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Sensitivity MFB HR versus NHR (Benign+LR) 3.bmpPooled sensitivity = 0.81 (0.46-0.98)Chi-square: 3.82; *P* = 0.2819Inconsistency: *I2*= 21.4% | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Specificity MFB HR versus (Benign+LR) 3.bmpPooled specificity= 0.77 (0.50-0.94)Chi-square: 0.64; *P* = 0.8865Inconsistency: *I2*= 0% |
| Zhang *et al*[20], 2018 | 3 | 1 | 1 | 5 | 0.75 (0.19-0.99) | 0.83 (0.36-1.00) |
| Basar *et al*[21], 2018 | 4 | 1 | 0 | 2 | 1.00 (0.40-1.00) | 0.67 (0.09-0.99) |
| Kovacevic[19], 2018 | 0 | 0 | 1 | 3 | 0.33 (0.00-0.98) | 0.86 (0.23-1.00) |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| Low Risk vs High Risk | Mittal *et al*[18], 2018 | 1  | 0 | 2 | 1 | 0.33 (0.01-0.91) | 1.00 (0.03-1.00) |  C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Sensitivity MFB LR versus HR 3.bmpPooled Sensitivity= 0.64 (0.33-0.88)Chi-square: 2.24 P-value=0.5246Inconsistency: I2=0% | C:\Users\user\Documents\Luísa\DrªSandraFaias\Nova Meta-análise cancro Pâncreas\Specificity MFB LR versus HR 3.bmpPooled Specificity= 0.81 (0.46-0.98)Chi-square: 3.82 P-value=0.2819Inconsistency: I2=21.4% |
| Zhang *et al*[20], 2018 | 4 | 1 | 1 | 3 | 0.80 (0.28-0.99) | 0.75 (0.19-0.99) |
| Basar *et al*[21], 2018 | 1 | 0 | 1 | 4 | 0.50 (0.01-0.99) | 1.00 (0.40-1.00) |
| Kovacevic[19], 2018 | 2 | 1 | 0 | 0 | 0.80 (0.12-1.00) | 0.33 (0.00-0.98) |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

**Figure 6 Forest plots of the included studies for microforceps biopsies.** In parentheses are the 95% confidence intervals (CI) of the sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (red circle) and its 95%CI (blue horizontal line). The area of the circle reflects the weight that the study contributes to the meta-analysis.

**Table 1 Characteristics of studies of molecular analysis included in the analysis**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study (study period)** | **Number of genes/DNA quantity, ng/microL(mean and interval)** | **Diagnosis** | **Sample size (all patients in the study)** | **Technical success (successful molecular analysis)** | **Adverse events (major/minor)** | **Diagnostic yield (patients with DNA mutations detected)**  | **Surgical cohort** | **Mean cyst size and range (mm)** | **Cysts < 3 cm** | **Cyst location****(H/B/T)****Cysts with mutations** | **Specific Cyst Diagnosis (MA/all patients)** | **Specific Cyst Diagnosis****(MA/surgical pathology)** | **High risk cysts****(MA/surgical pathology)** | **Mucinous low-risk cysts (MA/surgical pathology)** | **Benign cysts (MA/surgical pathology)** | **Specific cyst type (MA/surgical pathology)** |
| **IPMN-ADC** | **IPMN-HG** | **IPMN-LG** | **MCN-HG** | **MCN-LG** | **SCA** | **Pseudocyst** | **NET** | **Other4** |
| Jones *et al*[45], 2015 | Prospective(Mar 2013-Feb 2014) | 39/12.3 (0-1283) | Pathology or cytology | 86 | 79 (only 3 due to NGS failure) | NA | 46 | 10 | NA | NA | NA | 72/92 | 5/10 | 1/6 | 4/4 | 0/0 | 1/4 | 0/2 | 4/4 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 |
| Singhi *et al*[46], 2016 | Retrospective(Jan 2014-May 2015) | 6/NA | Pathology or clinicopathologic | 225 | 225 | NA | 118 | 41 | 2.8 (8-115) | 152 | 95/81/49 | 130/225 | 32/41 | 10/14 | 12/13 | 10/14 | 9/92 | 1/22 | 12/12 | 0/0 | 0/1 | 2/2 | 8/8 | 0/2 | 0/53 |
| Rosenbaum *et al*[32], 2016  | Retrospective (Mar 2013-Jun 2015) | 9/NA | Pathology or clinicopathologic | 105 | 105 | NA | 67 | 25 | NA | NA | NA | 67/1131 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Singhi *et al*[47], 2017 | Prospective (Jan 2014-Ju 2017) | 11/6.93 (0.01-248) | Pathology or cytology | 642 | 595 | NA | 335 | 102 | 2.7 (8-210) | NA | 320/B+T=306 | 357/626 | 77/102 | 17/29 | 41/47 | 19/26 | 13/13 | 4/43 | 39/39 | 0/2 | 2/8 | 2/3 | 17/17 | 0/9 | 0/73 |
|  |  |  |  | 1058 | 1004 | NA | 566 (54%) | 178 | 2,7(8-210) | 152 |  | 828/965 (86%) | 114/153 (74%) | 28/49(62%) | 57/64(89%) | 29/40(73%) | 23/26 | 5/8 | 55/55 | 0/2 | 2/9 | 4/5 | 25/25 | 0/11 | 0/12 |

1113 samples of 105 patients; 2*TP53, PIK3CA, PTEN*; 31 ACC; 4includes: ACC, retention cyst, lymphoepithelial cyst, epidermoid cyst, and squamoid cyst. MA: molecular analysis; NA: non-available data; ACC: acinar cell cyst; H/B/T: head body and tail of the pancreas; ADC: adenocarcinoma; HG: high-grade; LG: low-grade; NET: neuroendocrine tumor.

**Table 2 Characteristics of studies of microforceps biopsies included in the analysis**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study (study period)** | **Diagnosis** | **Sample size (all patients in the study)** | **Technical success (successful cyst puncture and biopsy)** | **Adverse events****(major/minor)** | **Diagnostic yield (histopathologic diagnosis available)** | **Surgical cohort** | **Mean cyst size and range,****(mm)** | **Cysts < 3 cm** | **Cyst location****(H/B/T)** | **Specific cyst diagnosis (MFB/all patients)** | **Specific cyst (MFB/surgical pathology)** | **High risk cysts****(MFB/surgical pathology)** | **Mucinous low risk cysts (MFB/surgical pathology)** | **Benign cysts (MFB/surgical pathology)** | **Specific cyst type (MFB/surgical pathology)** |
| **IPMN-ADC**  | **IPMN-HG** | **IPMN-LG** | **MCN-HG** | **MCN-LG** | **SCA** | **Pseudocyst** | **NET** | **Other (ACC)** |
| Mittal *et a*l[18], 2018 | Retrospective (Dec 2016-June 2017) | Pathology, cytology and cyst fluid analysis | 27 | 27 | 0/0 | 24 | 4 | 38 (15-70) | 20 | 14/B+T=13 | 24/27 | 2/4 | 1/1 | 1/3 | 0/0 | 0/0 | 0/0 | 12/3 | - | NA | - | - | 1/1 | - |
| Zhang *et a*l[20], 2018 | Retrospective (Jan 2016- Set 2017) | Pathology, cytology and cyst fluid analysis | 48 | 46 | 0/0 | 36 | 10 | 31 (12-60) | 23 | 13/22/13 | 24/48 | 7/10 | 3/4  | 4/5 | 1/1 | 11/3 | 13/0 | 4/4 | - | 01/1 | 1/1 | - | - | 1/1 |
| Basar *et a*l[21], 2018 | Retrospective (2015-2016) | Pathology, cytology and cyst fluid analysis | 42 | 38 | 0/2 | 26 | 7 | 28 (12-60) | 24 | 16/17/9 | 15/42 | 6/7 |  4/4 | 1/2 | 1/1 | 2/2 | - | 1/1 | - | 01/1 | 1/1 | - | 1/1 | 1/1 |
| Kovacevic *et a*l[19], 2018 | Retrospective (Sep 2016-Oct 2017) | Pathology or multidisciplinary conference | 31 | 27  | 1/2 | 22 | 4 | 34 (12-130) | 14 | NA/NA/NA | 244/31 | 3/4 | 0/1 | 2/2 | 1/1 | 0/1 | - | 33/2 | - | - | - | 1/1 | - | - |
|  |  |  | 148 | 138 | 1/4 | 108/148(73%) | 25 | 33 (12-130) | 81 |  | 63/148(42%) | 18/25 (72%) | 8/10 (80%) | 8/12(67%) | 3/3 (100%) | 3/6 | 1/0 | 8/10 | - | 0/2 | 2/2 | 1/1 | 2/2 | 2/2 |

11 nondiagnostic on MFB; 22 nondiagnostic on MFB; 31 false negative IPMN associated invasive carcinoma; 42 cases with a suspicion of pseudocyst. MFB: microforceps biopsy; NA: non-available data; ND: nondiagnostic; ACC: acinar cystadenoma; H/B/T: head body and tail of the pancreas; ADC: adenocarcinoma; HG: high-grade; LG: low-grade; NET: neuroendocrine tumor.